| SERCA (Sarco/Endoplasmic Reticulum Ca²⁺-ATPase) |
|---|
| Genes | [ATP2A1](/genes/atp2a1), [ATP2A2](/genes/atp2a2), [ATP2A3](/genes/atp2a3) |
| UniProt ID | [O14983](https://www.uniprot.org/uniprot/O14983) (SERCA1) |
| PDB | 1DQA, 2ZBD, 3N5K, 6KYT |
| Molecular Weight | 110 kDa |
| Localization | ER/SR membrane |
| Family | P-type ATPase family, IIA subgroup |
| Disease | Darier Disease, Brody Disease, AD |
The Sarco/Endoplasmic Reticulum Ca²⁺-ATPase (SERCA) is a P-type ATPase that actively pumps calcium ions from the cytosol into the endoplasmic/sarcoplasmic reticulum. This calcium reuptake is essential for terminating calcium signals, maintaining ER calcium stores, and enabling repeated signaling events. SERCA dysfunction contributes to calcium dyshomeostasis in neurodegeneration.
SERCA has a characteristic P-type ATPase structure with four functional domains:
- A-domain (Actuator): Involved in dephosphorylation and calcium release
- P-domain (Phosphorylation): Contains the conserved DKTGT phosphorylation motif
- N-domain (Nucleotide-binding): Binds ATP
- Transmembrane domain: 10 helices forming the calcium transport pathway
SERCA cycles through several conformational states (E1-E2 transition):
- E1: High Ca²⁺ affinity, cytosolic-facing binding sites
- E1~P: Phosphorylated, Ca²⁺ occluded
- E2~P: Low Ca²⁺ affinity, luminal release
- E2: Dephosphorylated, reset
Three isoforms exist:
- SERCA1 (ATP2A1): Fast-twitch skeletal muscle, Brody disease
- SERCA2 (ATP2A2): Widespread, brain (SERCA2b dominant), Darier disease
- SERCA3 (ATP2A3): Limited distribution, secretory cells
SERCA is critical for calcium homeostasis:
- Calcium Reuptake: Pumps 2 Ca²⁺ per ATP into ER lumen
- ER Calcium Loading: Maintains high luminal Ca²⁺ (mM range)
- Signal Termination: Ends Ca²⁺ transients rapidly
- Muscle Relaxation: In skeletal/cardiac muscle (SERCA1/2a)
- Protein Folding: ER chaperones require Ca²⁺ for function
- Store-Operated Calcium Entry (SOCE): STIM senses ER depletion via SERCA
SERCA activity is regulated by:
- Phospholamban: Inhibitory, relieved by PKA phosphorylation
- Sarcolipin: Inhibitory, controls heat production
- Calmodulin: Modulates activity
- ER calcium levels: Product inhibition at high luminal Ca²⁺
SERCA dysfunction in AD has complex implications:
Downregulation observed:
- Reduced SERCA2b expression in AD brain
- Contributes to ER calcium depletion
- Impaired protein folding capacity
Aβ effects on SERCA:
- Aβ oligomers may inhibit SERCA activity
- ER stress from reduced Ca²⁺ stores
- Compromised UPR response
Therapeutic considerations:
- SERCA activation may improve ER function
- BUT: Increased ER Ca²⁺ may enhance IP₃R/RyR release → excitotoxicity
- Balanced approach needed
SERCA involvement in PD:
- α-synuclein: Inhibits SERCA in cellular models
- MPTP models: Reduced SERCA expression
- DJ-1: Protects SERCA from oxidative damage
- mHtt disrupts ER calcium handling
- SERCA function compromised
- Contributes to calcium dyshomeostasis
¶ Bipolar Disorder and Depression
- SERCA implicated in mood regulation
- Some mood stabilizers affect SERCA
- Calcium signaling dysregulation hypothesis
| Agent |
Mechanism |
Status |
| CDN1163 |
SERCA activator |
Preclinical |
| Istaroxime |
SERCA2a activator |
Phase II (heart failure) |
| Thapsigargin |
SERCA inhibitor (research tool) |
Not therapeutic |
| Ispinesib |
SERCA2b upregulation |
Preclinical |
| Gene therapy |
AAV-SERCA2a |
Clinical (cardiac) |
SERCA activation strategy:
- May improve ER function in neurodegeneration
- Concern: Enhanced Ca²⁺ release via IP₃R/RyR
- Isoform-specific targeting needed